Business Development
Myrexis, Inc. is committed to developing first-in-class / best-in-class therapeutics for cancer and autoimmune diseases. To do this, we intend to develop strategic alliances with partners that can provide the expertise and resources to fully realize the potential of our novel development compounds and accelerate their path to market.
Our Current Partnering Opportunities include:
- Hsp90 Inhibitor Program for cancer
- MPC-8640 Cancer Metabolism Inhibitor
- MPI-485520 OAI for cancer and inflammation
- Azixa® (MPC-6827) brain targeted tubulin inhibitor for GBM
- HIV portfolio of viral maturation inhibitors
If you are interested in learning more about our development candidates or collaborating with Myrexis, Inc., please contact our Business Development group:
Wayne Laslie
Chief Operating Officer
(p) 801-214-7822
business.development@myrexis.com

